Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Dyne Therapeutics, Inc. (DYN)  
$8.17 0.34 (4.34%) as of 4:30 Thu 4/17


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 115,400,000
Market Cap: 942.82(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.81 - $47.04
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 32,000 1,746,285
Total Buy Value $0 $0 $1,057,216 $31,057,204
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 1 2
Total Shares Sold 16,140 425,672 2,975,844 8,427,712
Total Sell Value $200,187 $12,325,110 $118,639,492 $243,073,987
Total People Sold 5 6 9 13
Total Sell Transactions 9 20 85 178
End Date 2025-01-19 2024-10-18 2024-04-19 2023-04-20

   
Records found: 324
  Page 1 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Lucera Erick Chief Financial Officer   •       –      –    2025-03-31 4 A $0.00 $0 D/D 66,100 66,100     -
   Friedl-Naderer Johanna Chief Commercial Officer   •       –      –    2025-03-13 4 AS $12.12 $1,733 D/D (143) 96,057 -41%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2025-03-11 4 AS $11.38 $24,501 D/D (2,153) 195,840 -41%     
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2025-03-11 4 AS $11.38 $15,283 D/D (1,343) 122,330 -41%     
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2025-03-05 4 AS $11.83 $10,848 D/D (917) 123,673 -42%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2025-03-05 4 AS $11.83 $12,942 D/D (1,094) 197,993 -42%     
   Kerr Douglas Chief Medical Officer   •       –      –    2025-03-05 4 AS $11.83 $15,888 D/D (1,343) 94,157 -42%     
   Cox John CEO & President   •       •      –    2025-03-05 4 AS $11.83 $48,042 D/D (4,061) 146,239 -42%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2025-02-18 4 AS $13.95 $36,242 D/D (2,598) 199,087 -49%     
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2025-02-18 4 AS $13.95 $34,708 D/D (2,488) 124,590 -49%     
   Rhodes Jason P   –       •      –    2025-01-27 4 A $13.50 $14,999,999 I/I 1,111,111 1,958,427     -
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2024-12-11 4 AS $28.12 $40,915 D/D (1,455) 127,078 -74%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2024-12-11 4 AS $28.12 $65,632 D/D (2,334) 201,685 -74%     
   Kersten Dirk   –       •      –    2024-12-09 4 S $29.18 $1,004,872 I/I (34,437) 5,400,545 72%     
   Kersten Dirk   –       •      –    2024-12-06 4 S $29.34 $2,983,145 I/I (101,675) 5,434,982 72%     
   Kersten Dirk   –       •      –    2024-12-05 4 S $29.05 $110,564 I/I (3,806) 5,536,657 71%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2024-12-04 4 A $0.00 $0 D/D 66,500 204,019     -
   Friedl-Naderer Johanna Chief Commercial Officer   •       –      –    2024-12-04 4 A $0.00 $0 D/D 37,800 96,200     -
   Kersten Dirk   –       •      –    2024-12-04 4 S $29.39 $3,968,796 I/I (135,039) 5,540,463 73%     
   Cox John CEO & President   •       •      –    2024-12-04 4 A $0.00 $0 D/D 145,300 150,300     -
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2024-12-04 4 A $0.00 $0 D/D 32,700 128,533     -
   Kerr Douglas Chief Medical Officer   •       –      –    2024-12-04 4 A $0.00 $0 D/D 48,000 95,500     -
   Kersten Dirk   –       •      –    2024-12-03 4 S $29.05 $863,715 I/I (29,732) 5,675,502 72%     
   Kersten Dirk   –       •      –    2024-12-02 4 S $29.66 $2,409,294 I/I (81,201) 5,705,234 74%     
   Kersten Dirk   –       •      –    2024-11-14 4 AS $32.82 $293,050 I/I (8,929) 5,786,435 -62%     
  324 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us